Counselors in Enoch, UT Accepting Medicare
4 Counselors found. Showing 1 - 4
 Dustin Scott Orton Counselor - Mental Health Medicare: Not Enrolled in Medicare Practice Location: 3922 N Minersville Hwy, Enoch, UT 84721 Phone: 435-267-4212 |
 Mrs. Natalie Rae Haley, MS/MHC Counselor - Professional Medicare: Not Enrolled in Medicare Practice Location: 4375 N Maple Ln, Enoch, UT 84721 Phone: 435-691-2802 |
Amy Nielson, CMHC Counselor - Mental Health Medicare: Not Enrolled in Medicare Practice Location: 4562 N Oregon Trl, Enoch, UT 84721 Phone: 435-590-4417 |
William Chaze Palmer Counselor Medicare: Not Enrolled in Medicare Practice Location: 6484 N 2300 W, Enoch, UT 84721 Phone: 435-867-4876 |
News Archive
Vertebral and hip fractures are associated with an increased risk of death in people older than 50
Vertebral and hip fractures are associated with an increased risk of death, found a new study of 7753 people in Canada aged 50 years and older published in CMAJ (Canadian Medical Association Journal).
The Transcatheter Cardiovascular Therapeutics 2009 to feature PLCs' RenalGuard System
PLC Systems Inc. (OTC Bulletin Board: PLCSF), a company focused on innovative cardiac and vascular medical device-based technologies, today announced that it will demonstrate its RenalGuard System(TM) at Transcatheter Cardiovascular Therapeutics (TCT) 2009, sponsored by the Cardiovascular Research Foundation, September 21 - 25, 2009, in San Francisco, California. More than 11,000 clinicians and professionals are expected to attend this event.
Combination of two mTOR inhibitors stops growth of hepatocellular carcinoma
The combination of two inhibitors of protein mTOR stops the growth of primary liver cancer and destroys tumour cells, according to a study by researchers of the Group of Metabolism and Cancer at Bellvitge Biomedical Research Institute.
MicuRx announces initiation of global clinical development program for MRX-I compound
MicuRx Pharmaceuticals, Inc., a privately-held biopharmaceutical company developing next-generation antibiotics, today announced the initiation of a global clinical development program for its lead compound MRX-I, a novel oxazolidinone antibiotic for treatment of Gram-positive infections including methicillin-resistant Staphylococcus aureus and vancomycin-resistant enterococci.
› Verified 7 days ago